Evaluation of Hepatitis B Virus in Clinical Trials of Baricitinib in Rheumatoid Arthritis
RMD Open 2020;6:e001095
View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.
RMD Open 2020;6:e001095
Drug Saf. 2020;43:379-392
JAMA Dermatol 2020;156:649–58. doi 10.1001/jamadermatol.2020.0723
Blauvelt et al. shows superior and sustained efficacy for risankizumab in maintaining skin clearance over time versus placebo upon withdrawal, alongside a favourable safety profile in chronic plaque psoriasis through a phase 3, randomised, double-blind, placebo-controlled study, assessing PASI 90 and sPGA score of 0/1 at Week 16.
Pharmacodynamics. 2020
Int J Rheum Dis . 2020 Jan;23(1):65-73. doi: 10.1111/1756-185X.13748.
JAMA 2019 322(4):315-325
Lancet 2019;394:576–86. doi: 10.1016/S0140-6736(19)30952-3
Treatment with risankizumab showed significantly greater efficacy over adalimumab in providing substantial skin clearance in patients with moderate-to-severe chronic plaque PsO. This study aimed to assess the safety and efficacy of risankizumab compared with adalimumab in an active-comparator Phase 3 trial.
Lancet 2018 Dec 1;392(10162):2378-2387. DOI 10.1016/S0140-6736(18)32463-2
Lancet. 2018 Dec 1;392(10162):2367-2377. DOI 10.1016/ S0140-6736(18)32483-8
J Rheumatol. 2019 Jan;46(1):7-18. DOI: 10.3899/jrheum.171361